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To investigate the role of metabotrophic purinergic P2Y receptors in neuroblastoma cell survival, expres-
sion of P2 receptors by normal mouse (C57BL/6) brain and human neuroblastoma SH-SY5Y cells was 
investigated by Western blot and real time PCR studies. Viability of SH-SY5Y cells treated with puriner-
gic receptor antagonists suramin and pyridoxal-phosphate-6-azophenyl-2’,4’-disulfonate (PPADS) was 
evaluated by MTT assay and flow cytometry. In the brain samples of C57BL/6 mice, expressions of P2Y4 
and P2X7 were significantly reduced, whereas that of P2Y1 was significantly elevated in an age-depend-
ent manner. SH-SY5Y cell viability was significantly reduced and necrotic cell rates were mildly 
increased by 400 µM suramin and 100 µM PPADS treatment. Antagonist treatment downregulated P2Y1, 
P2Y2 and P2Y4 and upregulated P2Y6, P2Y12 and P2X7 mRNA levels in SH-SY5Y cells on the 24th 
hour. These alterations were abolished for all P2 receptors except P2Y1 in the 48th hour. P2Y receptors 
are expressed by both normal mouse brain and human neuroblastoma cells. Purinergic receptor antago-
nism interferes with neuroblastoma viability through elevation of necrotic cell death and modulation of 
P2 receptor expression. P2Y receptors might thus be useful targets for future anti-tumor treatment trials.
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INTRODUCTION
Purinergic signalling is critical for proper functioning of the nervous system. 
Purinergic receptors play crucial roles in a variety of neurological disorders such as 
epilepsy and depression and contribute to the progression of several types of tumors 
such as glioma and neuroblastoma [11]. Moreover, recent evidence suggests that 
disturbance of the P2Y and P2X receptor signalling and changes in expression of 
extracellular ectonucleotidases interfere with normal neuronal aging and facilitate 
neurodegeneration [14].  
Neuroblastoma is a malignant tumor originating from neuroectodermal cells, and 
it is the second most common solid tumor in children and is commonly associated 
with high rates of metastasis and low rates of survival despite early diagnosis and 
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intensive cancer therapy [8]. The control of neuroblastoma progression involves sev-
eral intracellular signalling pathways, including those related with purinergic P2 
receptors [1, 3–5, 7, 12]. Although ATP is secreted in an autocrine fashion to achieve 
certain physiological functions, it is present at almost undetectable level in the normal 
interstitial tissue [10]. By contrast, ATP released from tumor cells is accumulated at 
the interstitium of the cancer tissue (including that of neuroblastoma) at very high 
concentrations and plays an important role in tumor progression [3].
In this study, first, expression of purinergic P2 receptors that are known to be 
involved in cell viability [1, 3–5, 7, 11, 12] was examined in the aging mouse brain. 
Next, we identified the impact of P2 receptor antagonists on the viability, cell death 
and purinergic receptor expression of human SH-SY5Y neuroblastoma cells. Our 
results emphasize P2Y receptors as major role players in neuroblastoma progression 
and a potential target in anti-tumor therapy.
MATERIAL AND METHODS
Mice
Expression levels and age-dependent variations of several purinergic receptors were 
investigated in the mouse brain due to unavailability of human tissue samples. Male 
C57BL/6 (B6) mice from different ages (3, 9 and 15 month-old; n = 5 for each age 
group) were obtained from the animal facility of Aziz Sancar Institute of Experimental 
Medicine. Mice were housed in a viral antibody-free barrier facility and maintained 
according to the Institutional Animal Care and Use Committee Guidelines. The study 
was approved by the Institutional Review Board.
Immunoblotting analyses
Brain samples were rapidly obtained from each mouse following decapitation and 
protein concentrations were determined with a BCA detection kit. Twenty micro-
grams of each brain lysate was loaded and separated by 4–20% SDS-polyacrylamide 
gradient gel electrophoresis and then transferred to 0.45 μm polyvinylidene fluoride 
membranes (100 V, 80 min). After blocking for 1 hour in PBST (10 mm sodium 
phosphate, 0.9% NaCl and 0.1% Tween 20) containing 5% non-fat dry milk, blots 
were incubated overnight at 4 °C with goat anti-mouse P2Y1, P2Y2, P2Y4, P2Y6, 
P2Y12, P2X7 and β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) anti-
bodies in PBST containing 5% non-fat milk. The blots were washed with PBST and 
incubated for 1 hour with horseradish peroxidase-conjugated rabbit anti-goat (Santa 
Cruz Biotechnology) diluted in PBST. Immunoreactivity of the protein bands were 
detected by enhanced chemiluminescent autoradiography (ECL kit, Amersham 
Pharmacia Biotech, Piscataway, NJ). A molecular weight standard (Bio-Rad 
Laboratories, Hercules, CA) was used to evaluate the molecular weight of detected 
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bands. The immunoblot bands were quantified through measurement of band inten-
sity with ImageJ software using the same pixel scale for all pictures. Band intensities 
were normalized by β-actin expression and expressed as arbitrary units. 
Cell viability assessment
Human SH-SY5Y cells (ATCC, Wesel, Germany) were grown in DMEM/F12 (1:1) 
media supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/
ml streptomycin. The cells were plated in 96-well plates at a density of 1×105 cells/
well with or without P2 purinergic receptor antagonists suramin (400 µM) or pyridox-
al-phosphate-6-azophenyl-2’,4’-disulfonate (PPADS) (100 µM) for 12, 24, 48 and 72 
hours. The plated cells were maintained at 37 °C in 95% humidified atmosphere with 
5% CO2. Six separate wells were used for each antagonist and time duration. 
Antagonist concentrations were selected according to results obtained in preliminary 
experiments. The media was changed with one containing 0.5 mg/ml MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide). Four hours later, 
the media was gently removed and the precipitations in each well were dissolved in 
100 μl of DMSO. The absorbance at 570 nm was measured using a microplate reader 
and expressed as OD.
Flow cytometry
In a second experiment, SH-SY5Y cells were plated in 96-well plates at a density of 
1×105 cells/well and treated with or without 400 µM suramin and 100 µM PPADS for 
24 or 48 hours. Six separate wells were used for each antagonist and time duration. 
After treatment, cells were collected and washed with cold PBS. Annexin V-fluorescein 
isothiocyanate (FITC; 5 μL) and propidium iodide (PI) staining solution (5 μL) were 
added and cells were then incubated for 20 minutes in the dark. The apoptosis and 
necrosis rates were measured through flow cytometry (Beckman, Brea, CA). 
Real time PCR
In the last experiment performed using the same experimental setting in 96-well 
plates (six wells for each parameter), SH-SY5Y cells were collected after incubation 
with or without 400 µM suramin and 100 µM PPADS for 24 or 48 hours. Total RNA 
from each well was isolated using Trizol Reagent (InVitrogen, Carlsbad, CA, USA) 
and RNA was quantified by OD260. Four micrograms of total mRNA were reverse 
transcribed using superscript II reverse transcriptase and oligodT primer (InVitrogen). 
Specific primers (Table 1) were selected using primer3 software and generated by 
Qiagen (Hilden, Germany). The specificity of the primers was verified with a Blast 
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search through NCBI. The quantitative real-time PCR reactions were performed with 
the SYBR Green kit (Roche Diagnostics, Mannheim, Germany) using 2 μl of cDNA 
and 0.6 μl of each primer in a 20 μl final volume. Quantitative PCR was performed 
using Light Cycler (Roche Diagnostics) for 40 cycles at 95 °C 15 seconds, annealing 
temperature of 60 °C for 20 seconds and 72 °C for 30 seconds. All samples were 
studied as duplicates and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
used as a reference gene. Data were analyzed according to the ΔΔCt method and the 
results were expressed as relative mRNA levels.
Statistical analysis
Multiple group comparisons among different treatment arms were performed with 
ANOVA and Tukey’s post-hoc test. p values for ANOVA are provided in the text, 
whereas p values for two-group comparisons are indicated in the figures. p < 0.05 was 
considered as statistically significant.
RESULTS
Age-dependent variation of cerebral P2 receptor expression
The presence and expression levels of major cell survival-related purinergic P2 recep-
tors in the mouse brain were investigated by immunoblotting analyses using a semi-
quantitative measurement method. Brain samples of mice from different ages exhib-
ited P2Y1, P2Y2, P2Y4, P2Y6, P2Y12 and P2X7 receptors at varying expression 
levels. Notably, expression levels of P2Y1, P2Y2 and P2Y6 receptors showed trends 
towards increasing, while those of P2Y4 and P2X7 showed trends towards decreasing 
Table 1
Quantitative polymerase chain reaction primers
Primer name Forward primer (5’-’3) Reverse primer (3’-’5)
P2Y1 CGACAGGGTTTATGCCACTT TCGTGTCTCCATTCTGCTTG
P2Y2 AGCCCATTACGTGACTGTCC CTGAGGCAGGAAACAGGAAG
P2Y4 AACCAGGAAGCTGGGGTACT GGAGGTTCCTTAGGGTCAGC
P2Y6 GGAACACCAAATCTGGCACT GTATACCGGGGTTAGCAGCA
P2Y12 TGGGCGTACCCTACAGAAAC AGGTGGTATTGGCTGAGGTG
P2X7 CCACCTTCAAAACCACGTCT AAGCTCTTTTCCCACCCCTA
GAPDH* AGGGCTGCTTTTAACTCTGGT CCCCACTTGATTTTGGAGGGA
*Indicates housekeeping gene GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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in an age-dependent manner and P2Y12 expression levels remained stable at different 
ages. These alterations attained statistical significance only for P2Y1, P2Y4 and 
P2X7 receptors (p < 0.001, p = 0.002 and p = 0.003, respectively) (Fig. 1).
Cell viability of SH-SY5Y cells are reduced by P2 receptor antagonists
The impact of purinergic P2 receptor antagonists on SH-SY5Y cell viability was 
assessed by MTT assay. Both suramin and PPADS significantly suppressed SH-SY5Y 
viability by the 12th and 24th hours (p < 0.001 for both time points). At the 48th hour, 
PPADS treated cells continued displaying reduced viability as compared to non-
treated and suramin-treated cells (p < 0.001). By the 72nd hour, all treatment arms 
showed comparable viability levels (p = 0.355, Fig. 2). MTT experiments also 
showed that the critical time for the alteration of cellular proliferation for antagonist 
administered SH-SY5Y cells was 24–48 hours. Therefore remaining experiments 
were done for these two specific time points.
P2 receptor antagonists induce a moderate increase 
in SH-SY5Y necrosis rates
To evaluate whether cell viability reduction of P2 receptor antagonist administered 
SH-SY5Y cells was due to necrotic or apoptotic cell death, flow cytometry analysis 
was performed using PI-Annexin V staining. No appreciable apoptotic (Annexin V+ 
cells) cell death  was observed in SH-SY5Y cells treated with or without purinergic 
P2 receptor antagonists at the 24th and 48th hours of incubation (Table 2). By con-
trast, treatment with both 400 µM suramin and 100 µM PPADS induced mildly but 
significantly increased necrosis (PI+Annexin V-cells) rates as compared to non-
treated cells at the 24th hour of incubation (Fig. 3). However, the necrosis rate differ-
ence between treatment groups was abolished on the 48th hour of incubation 
(Table 2).
Table 2
Necrotic and apoptotic cell death rates of purinergic receptor antagonist administered SH-SY5Y cells  
as assessed by flow cytometry analysis of propidium iodide (PI) and Annexin V staining
24 hours 48 hours
PI+
Annexin V–
PI+
Annexin V+
PI–
Annexin V+
PI+
Annexin V–
PI+
Annexin V+
PI–
Annexin V+
None 6.9±0.2 0.1±0.1 0.0±0.0 9.6±0.8 0.1±0.1 0.1±0.1
400 µM  
suramin 11.1±0.3 0.2±0.1 0.1±0.1 9.9±0.5 0.1±0.1 0.1±0.1
100 µM 
PPADS 12.3±0.8 0.1±0.1 0.0±0.0 10.3±0.8 0.1±0.1 0.1±0.1
p value <0.001 0.776 0.861 0.196 0.854 0.957
PPADS, pyridoxal-phosphate-6-azophenyl-2’,4’-disulfonate. Data are expressed as mean ± standard deviation.
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P2 receptor expression variations of antagonist-treated SH-SY5Y cells
Impact of purinergic P2 receptor antagonists on expression levels of various P2 
receptors was evaluated by real time PCR studies with the same experimental setting 
used in previous experiments. At the 24th hour of incubation, both suramin and 
PPADS-treated SH-SY5Y cells showed significantly reduced P2Y1 (p = 0.001), 
P2Y2 (p = 0.012) and P2Y4 (p < 0.001) expression levels and significantly increased 
P2Y6 (p < 0.001), P2Y12 (p < 0.001) and P2X7 (p = 0.019) expression levels. These 
differences were abolished on 48th hour of incubation for P2Y2 (p = 0.521), P2Y4 
(p = 0.489), P2Y6 (p = 0.830), P2Y12 (p = 0.678) and P2X7 (p = 0.122) receptors. 
By contrast, PPADS-treated cells showed significantly lower P2Y1 expression levels 
(p < 0.001) than suramin-treated and non-treated cells at the 48th hour of incubation 
(Fig. 4).
DISCUSSION
Neuronal vulnerability is known to increase by advancing age and the purinergic 
signalling is one of the mechanisms by which this is evoked. In the aging brain cells, 
interstitial ATP concentrations as well as purinergic receptor and neurotransmitter 
expression levels have been shown to change in parallel to each other [9]. In our 
study, we have shown that expression levels of most purinergic P2 receptors do not 
exhibit a steady-state pattern and show variations throughout the life span of mice. 
This might presumably be a compensatory adaptation for different neuronal prolif-
eration requirements in the advancing stages of life. P2X7 has been strongly associ-
ated with neuronal cell viability [3, 5, 7, 12] and thus decreased expression of P2X7 
might be one of the factors causing neuronal cell loss in advanced ages. In viability 
assays, P2Y1 downregulation was associated with reduced neuroblastoma cell sur-
vival and increased necrosis. Upregulation of this receptor might potentially be a 
compensating mechanism to counteract increasing neuronal death in the aging mouse 
brain. The validity of these assumptions and meaning of P2 receptor expression 
changes at different ages need to be further studied preferably on human brain sam-
ples.
Very likely to previous studies [4], SH-SY5Y cells were shown to express P2X7, 
P2Y1, P2Y2, P2Y4 and P2Y6 receptors. However, in contrast to a recent study con-
ducted by immunoblot analysis [4], we have also shown the expression of P2Y12 by 
SH-SY5Y cells using quantitative real time PCR analysis. This discrepancy might 
possibly be due to higher sensitivity of our quantitative PCR method. 
Although a wide variety of P2 receptors has been shown to be expressed by neu-
roblastoma cells, little is known about the role of purinergic signalling in neuroblas-
toma progression and P2X7, an ionotropic receptor, is the most extensively studied 
purinergic receptor in this context. P2X7 stimulation by ATP might be promoting 
neuroblastoma progression by enhancing release of locally acting trophic factors, 
maintaining calcium homeostasis through modulation of voltage-dependent calcium 
32 ArdA ÖrÇen et al.
Acta Biologica Hungarica 68, 2017
channel functions and activating the phosphatidylinositol 3-kinase (PI3K)-Akt cell 
survival pathway [3, 5, 7, 12]. There is few evidence on the involvement of metabo-
tropic P2Y receptors in neuroblastoma progression. In this context, P2Y6 stimulation 
by UDP has been shown to exert a cytotoxic effect on human neuroblastoma 
SH-SY5Y cells [1]. In another study, transient activation of P2Y4 increased SH-SY5Y 
cell differentiation, while prolonged activation of the same receptor induced cell 
death [4].
In our study, we have shown that treatment of SH-SY5Y cells with non-selective 
global antagonists of P2 receptors, suramin and PPADS induces a remarkable but 
short-lived and transient reduction in cell viability, as measured by the MTT assay. 
We have also shown that PPADS has a longer duration of impact on SH-SY5Y cell 
viability than suramin. This reduced viability could potentially be due to reduced 
metabolic activity or reduced number of live cells or both. Our flow cytometry results 
suggest that P2 receptor antagonism has a marginal impact on cell death via necrotic 
but not apoptotic mechanisms. Also, this effect disappears at the 48th hour of treat-
ment, while the viability reducing effect of PPADS continues at that time. Therefore, 
especially for PPADS, it is more likely that altered cellular metabolic activity is one 
of the mechanisms by which purinergic receptor antagonism reduces SH-SY5Y via-
bility. Conceivably, suramin and PPADS might have altered cell survival via non-P2 
receptor associated pathways or as a consequence of general toxicity. Therefore, uti-
lization of cell lines that do not express P2 receptors is recommended to better char-
acterize the involvement of P2X and P2Y receptors in cell survival. 
Real time PCR studies showed that in concurrence with P2 antagonist-mediated 
reduction in cell viability, expression levels of all investigated P2 receptors were 
effectively altered. Although we have not identified the exact roles of P2 receptor 
expression changes in viability of neuroblastoma cells, certain conclusions can be 
drawn. P2Y6 receptor stimulation is known to cause toxicity in SH-SY5Y cells [1] 
and thus increased expression of this receptor following P2 antagonist treatment 
might have contributed to cell death via extracellular ATP released by neuroblastoma 
cells. P2X7 promotes neuroblastoma proliferation [5] and thus increased expression 
of this receptor might be a compensating measure to counteract decreased cell viabil-
ity in the presence of purinergic antagonists. Short-term stimulation of P2Y4 leads to 
activation of differentiation pathways in SH-SY5Y cells [4] and thus downregulation 
of this receptor after antagonist treatment might also have led to reduced viability in 
neuroblastoma cells. Notably, while expression alterations of all P2 receptors were 
abolished at the 48th hour of the purinergic antagonist treatment, very likely to MTT 
assay results, the P2Y1 receptor expression kept being downregulated in PPADS but 
not suramin-treated cells. This suggests that selective prolonged inhibition of P2Y1 
is the underlying factor for prolonged activity of PPADS. This notion needs to be 
supported by experiments conducted with selective P2Y1 receptor antagonists.
As a limitation of our study, we have not investigated P2 receptor production at 
protein level. It is well known that post-translational modifications might impede P2 
receptor production and thus mRNA expression levels might not always reflect pro-
tein production levels of P2 receptors. Also, different post-translational modifications 
P2Y receptors in neuroblastoma viability 33
Acta Biologica Hungarica 68, 2017
of P2 receptors may lead to activation of diverse pathways within the cell [2, 6]. We 
did not study either the mechanisms underlying suramin- and PPADS-mediated P2 
receptor expression changes. P2X4 receptor expression of microglial cells have 
recently been shown to be modulated by PI3K-Akt and mitogen-activated protein 
kinase kinase (MAPK kinase, MEK)-extracellular signal-regulated kinase (ERK) 
pathways. Moreover, a translational factor has been demonstrated to alter P2X4 
receptor production through the MEK-ERK pathway [13]. Thus, parallel measure-
ment of mRNA and protein level of P2 receptors and post-translational mechanisms 
controlling expression and intracellular functions of P2 receptors are recommended 
to be investigated in future experiments.
It is well known that different cancer types show varied viability patterns in 
response to purinergic antagonism depending on the panel of purinergic receptors 
expressed by individual cancer cells. For instance, Caco-2 human colonic cancer cells 
show increased viability in the presence of suramin and reduced viability when 
stimulated by purinergic agonists [15]. Our results show that the panel of receptors 
expressed by SH-SY5Y cells lead to reduced viability in response to purinergic 
antagonists. Overall, our results indicate that P2 antagonists might potentially be used 
as markers of treatment response for neuroblastoma patients and they might also 
serve as potential future targets for neuroblastoma treatment.
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